

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **MING, ET AL.** :

APPLICATION NO.: **NOT YET ASSIGNED** : Examiner: **NOT ASSIGNED**

FILING DATE: **HEREWITH** : Group Art Unit: **NOT ASSIGNED**

TITLE: **NOVEL CRYSTALLINE FORMS OF:
3-ISOPROPYL-6-[4-(2,5-DIFLUORO-
PHENYL)-OXAZOL-5-YL]-
[1,2,4]TRIAZOLO-[4,3-A]PYRIDINES** :

Mail Stop PATENT APPLICATION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicants, copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).


Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date:

August 27, 2003


GARTH BUTTERFIELD
Attorney for Applicants
Reg. No. 36,997

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 573-1229

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>									ATTY. DOCKET NO. PC25312A			SERIAL NO. NOT ASSIGNED		
APPLICANT KANG, ET AL.									FILING DATE HEREWITH			GROUP NOT ASSIGNED		

U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5	7	1	6	9	5	5	2/10/98	ADAMS, ET AL	514	235.8	
		5	7	1	6	9	7	2	2/10/98	ADAMS, ET AL.	514	341	
		5	7	1	7	1	0	0	2/10/98	SELNICK, ET AL.	546	194	
		5	7	5	6	4	9	9	5/26/98	ADAMS, ET AL.	514	235.8	
		5	7	7	7	0	9	7	7/7/98	LEE, ET AL.	536	24.31	
		6	2	8	8	0	6	2	9/11/01	ADAMS, ET AL.	514	236.8	

FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
		9	9	0	1	4	4	9	1/14/99	PCT	C07D	401/04		
		9	9	6	1	4	4	0	12/2/99	PCT	C07D	403/14		
		0	0	0	6	5	6	3	2/10/00	PCT	C07D	401/04		
		0	0	3	1	0	6	5	6/2/00	PCT	C07D	401/04		
		0	0	3	5	9	1	1	6/22/00	PCT	C07D	405/14		
		0	0	4	0	2	4	3	7/13/00	PCT	A61K	31/444		
		0	0	4	1	6	9	8	7/20/00	PCT	A61K	31/535		
		0	0	6	3	2	0	4	10/26/00	PCT	C07D	413/00		
		0	2	7	2	5	7	6	9/19/02	PCT	C07D	403/14		
		0	2	7	2	5	7	9	9/19/02	PCT	C07D	471/04		
		1	2	4	7	8	1	0	10/9/02	EP	C07D	403/04		

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>													
		The Journal of Biological Chemistry, Vol. 271, No. 40, pp. 24313-24316 (1996);											
		Bioorganic & Medicinal Chemistry Letters, 10, pp. 2047-2050 (2000); and											
		Bioorganic & Medicinal Chemistry Letters, 11, pp. 9-12 (2001).											

EXAMINER	DATE CONSIDERED
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	